The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis

    Research output: Contribution to journalArticleResearchpeer-review

    86 Citations (Scopus)


    The activins, as members of the transforming growth factor-beta superfamily, are pleiotrophic regulators of cell development and function, including cells of the myeloid and lymphoid lineages. Clinical and animal studies have shown that activin levels increase in both acute and chronic inflammation, and are frequently indicators of disease severity. Moreover, inhibition of activin action can reduce inflammation, damage, fibrosis and morbidity/mortality in various disease models. Consequently, activin A and, more recently, activin B are emerging as important diagnostic tools and therapeutic targets in inflammatory and fibrotic diseases. Activin antagonists such as follistatin, an endogenous activin-binding protein, offer considerable promise as therapies in conditions as diverse as sepsis, liver fibrosis, acute lung injury, asthma, wound healing and ischaemia-reperfusion injury.
    Original languageEnglish
    Pages (from-to)285 - 295
    Number of pages11
    JournalCytokine and Growth Factor Reviews
    Issue number3
    Publication statusPublished - 2013

    Cite this